Kairos Pharma (NYSEAMERICAN:KAPA) Receives “Buy” Rating from D. Boral Capital
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. Kairos Pharma Price Performance KAPA opened at $1.32 on Tuesday. Kairos Pharma has a fifty-two […]
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. Kairos Pharma Price Performance KAPA opened at $1.32 on Tuesday. Kairos Pharma has a fifty-two […]
